TABLE 1

Animal characterization

ControlSTZSTZ-IRB
Blood pressure
    SAP at the beginning of the study (mmHg)114.5 ± 5.8119.1 ± 4.1121.6 ± 4.2
    SAP at the end of the study (mmHg)117 ± 6.969 ± 1.3*72 ± 1.9*
Body and heart weight
    Body weight at the beginning of the study (g)21.2 ± 1.220.4 ± 1.322.1 ± 1.4
    Body weight at the end of study (g)28.2 ± 1.218.1 ± 1.1*17.6 ± 1.2*
    Heart weight (mg)132 ± 589 ± 3*90 ± 4*
    Heart/body weight (mg/g)4.7 ± 0.44.9 ± 0.65.0 ± 0.4
Glucose levels
    Glucose level after 8 weeks of diabetes (mmol/l)4.4 ± 0.334.6 ± 1.9*36.4 ± 1.3
  • General characteristics of controls, mice with STZ-induced diabetes, and diabetic mice treated with irbesartan (STZ-IRB).

  • *

    * P < 0.05 vs. controls. SAP, systolic arterial pressure.